Chemours (CC) Liabilities and Shareholders Equity (2014 - 2026)

Chemours' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $7.3 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 1.48% year-over-year to $7.3 billion in Q1 2026; TTM through Mar 2026 was $29.7 billion, a 0.23% change from a year earlier, with the FY2025 full-year figure at $7.4 billion, down 1.69% from the prior year.
• Liabilities and Shareholders Equity eased to $7.3 billion in Q1 2026 per CC's latest filing, from $7.4 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $8.2 billion in Q4 2023 and bottomed at $7.2 billion in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $7.5 billion (2025), against an average of $7.6 billion.
• Across the five-year window, Liabilities and Shareholders Equity advanced 7.87% in 2023 and fell 8.88% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $7.6 billion in 2022, then gained by 7.87% to $8.2 billion in 2023, then slipped by 8.88% to $7.5 billion in 2024, then declined by 1.69% to $7.4 billion in 2025, then dropped by 1.56% to $7.3 billion in 2026.
• Per Business Quant, the three latest CC Liabilities and Shareholders Equity figures stand at $7.3 billion (Q1 2026), $7.4 billion (Q4 2025), and $7.5 billion (Q3 2025).